Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
DEFA14A - Autonomix Medical, Inc. (0001617867) (Filer)
DEF 14A - Autonomix Medical, Inc. (0001617867) (Filer)
424B3 - Autonomix Medical, Inc. (0001617867) (Filer)
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company's recently announced results from the post hoc analysis of its proof-of-concept human clinical trial ("PoC 1") THE WOODLANDS, TX, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the release of a Virtual Investor "What This Means" segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company's recently announced longer-term post hoc analysis re
New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain 100% of responders (n=7) 1 showed zero opioid use at their 3-month post-procedure follow-up2 Quality of life markers further improved including sleep quality, energy level and ability to lead normal daily and leisure time activities and reduced tension, vomiting and constipation THE WOODLANDS, TX, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted t
THE WOODLANDS, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY. In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more informa
4 - Autonomix Medical, Inc. (0001617867) (Issuer)
4 - Autonomix Medical, Inc. (0001617867) (Issuer)
4 - Autonomix Medical, Inc. (0001617867) (Issuer)
Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains on track to submit an Investigational Device Exemption ("IDE"), and if approved, will commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced th
Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman
Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c
SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)
SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)
SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)